Pereira-Miguel J M, Correa-Nunes A, Rocha-Gonçalves F, Mariano-Pego G
Department of Preventive Medicine, Medical Faculty, University of Lisbon, Portugal.
J Cardiovasc Pharmacol. 1992;19 Suppl 3:S49-52.
A short-term trial of isradipine was conducted to assess its effectiveness and tolerability in the treatment of mild-to-moderate hypertension. The study was carried out by general practitioners and involved 2,702 patients, aged 18-70 years, who had diastolic blood pressures (DBP) of 95-114 mm Hg. Patients completed a pretreatment phase of up to 4 weeks for antihypertensive drug washout and placebo run-in, before entering a 12-week active-treatment phase with 1.25 mg of isradipine twice daily, which was increased after 4 weeks to 2.5 mg twice daily, depending on the blood pressure response. At the end of 12 weeks, the mean systolic blood pressure (SBP) and DBP were 148.1 and 86.7 mm Hg compared with 169.0 and 103.0 mm Hg after placebo, respectively. The majority of patients (89.6%) had a DBP reduction greater than 10 mm Hg, and 86.2% had normalized DBP (less than or equal to 90 mm Hg) at the end of treatment. Adverse events were reported by 2.8% of patients, and 90% of patients and general practitioners reported satisfaction with the treatment. Thus, our results indicate that isradipine is effective and well tolerated, and may deserve a place as first-line treatment in mild-to-moderate hypertension.
进行了一项关于伊拉地平的短期试验，以评估其治疗轻至中度高血压的有效性和耐受性。该研究由全科医生开展，涉及2702名年龄在18至70岁之间、舒张压（DBP）为95至114毫米汞柱的患者。患者在进入为期12周的积极治疗阶段之前，先完成了长达4周的预处理阶段，以进行抗高血压药物洗脱和安慰剂导入。在积极治疗阶段，患者每日两次服用1.25毫克伊拉地平，4周后根据血压反应将剂量增至每日两次2.5毫克。12周结束时，平均收缩压（SBP）和舒张压分别为148.1毫米汞柱和86.7毫米汞柱，而安慰剂治疗后分别为169.0毫米汞柱和103.0毫米汞柱。大多数患者（89.6%）舒张压降低超过10毫米汞柱，86.2%的患者在治疗结束时舒张压恢复正常（小于或等于90毫米汞柱）。2.8%的患者报告了不良事件，90%的患者和全科医生对治疗表示满意。因此，我们的结果表明，伊拉地平有效且耐受性良好，在轻至中度高血压的一线治疗中可能值得占有一席之地。
